Last edition
News about "antibody-drug conjugates "
The partnership aims to speed up market entry for biopharma firms by combining Mycenax's biologics expertise with Spera Pharma’s high-potent fill-finish capabilities, offering an integrated, cost-effective ADC development platform.
Antibody-Drug Conjugates | 15/09/2025 | By Dineshwori
Veranova's Devens Site Clears FDA Inspection with Zero Observations
Veranova's Devens site has successfully completed a routine current Good Manufacturing Practice (cGMP) surveillance inspection by the Food and Drug Administration (FDA).
Antibody-drug Conjugates | 14/08/2025 | By Dineshwori | 104
Veranova Names Thomas Rohrer as Vice President of Bioconjugation
Veranova, a global leader in the development and manufacturing of specialty and complex active pharmaceutical ingredients (API) for the pharmaceutical and biotech sectors, has appointed Thomas Rohrer as Vice President of Bioconjugation.
Antibody Drug Conjugates | 29/07/2025 | By Dineshwori
Curia Plans Expansion to Global Network of Sterile Fill-Finish Sites
Curia’s sterile fill-finish facility in Glasgow will add an integrated, isolator-based vial filling line and lyophilizer suitable for a broad range of drug product including highly potent capabilities, more than doubling current GMP batch size.
Antibody Drug Conjugates | 18/03/2025 | By Aishwarya | 348
Novo Holdings Invests in Series A Launch Financing for Callio Therapeutics
The oversubscribed Series A financing was led by Frazier Life Sciences, with significant participation from Novo Holdings and other life sciences investors including Jeito Capital, Omega Funds, Norwest, ClavystBio, EDBI, Platanus, Pureos Bioventures and SEEDS Capital.
Antibody-drug Conjugates | 04/03/2025 | By Aishwarya | 282
Lantern Pharma Launches Innovative AI-Powered Module to Advance ADC Development for Cancer
The global ADC market is projected to reach USD 30.4 billion by 2028, growing at a CAGR of 41.7 percent, with several recently approved ADCs achieving blockbuster status with annual sales exceeding USD 1 billion.
Antibody-drug Conjugates | 28/01/2025 | By Aishwarya | 200
NJ Bio Partners with Charles River to Accelerate ADC Development
The biggest benefit of the Charles River and NJ Bio alliance is that clients can receive seamless complementary services to enhance outcomes and accelerate time-to-market for their ADCs.
Antibody Drug Conjugates | 08/11/2024 | By Aishwarya | 187
AstraZeneca to Establish USD 1.5 Billion Manufacturing Facility for ADCs in Singapore
AstraZeneca has decided to build a USD 1.5 billion manufacturing facility in Singapore for antibody-drug conjugates (ADCs), enhancing the global supply of its ADC portfolio.
Antibody-drug Conjugates | 20/05/2024 | By Aishwarya | 282
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy